AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (ABCL) Stock Price, Analysis & Data
| Cours acheteur | 7.26 |
| Capitalisation boursière | 2.99B |
| Chiffre d’affaires (ttm) | 66.17M |
| Résultat net (ttm) | -164.66M |
| Bêta | 1.19 |
| EPS (ttm) | -0.54 |
| Ratio P/E (ttm) | n/a |
| P/E prévisionnel | -13.65 |
| P/B (ttm) | 3.34 |
| P/S (ttm) | 45.22 |
| Earnings Date | Nov 5, 2026 |
| Cours vendeur | 11.66 |
| Volume | 17,223,620 |
| Volume moy. (20D) | 7,727,175 |
| Ouverture | 9.44 |
| Clôture précédente | 9.34 |
| Fourchette du jour | 9.02 - 10.29 |
| Intervalle de 52 semaines | 2.75 - 10.29 |
| Analyste | Strong Buy |
| Objectif de prix | 15 (53.69%) |
| Dividendes | n/a |
| Date ex-dividende | n/a |
À propos de ABCL
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, su...
Performance financière
En 2025, le chiffre d’affaires de AbCellera Biologics s’élevait à 75.13M, soit une hausse de 160.56% par rapport aux 28.83M de l’année précédente. Le bénéfice s’élevait à -146.41M, soit une baisse de -10.1%.
États financiersPrévisions des analystes
Selon les évaluations de 8 analystes, la note moyenne de l’action ABCL est « Strong Buy ». L’objectif de cours moyen à 12 mois est de 15, soit une hausse de 53.69 % par rapport au dernier cours.
Prévisions boursièresSurprise sur les résultats
Les analystes prévoient un chiffre d’affaires de ... Passer à l’offre supérieure
42 minutes il y a · Simply Wall St.
AbCellera Biologics (ABCL) Is Up 60.3% After Strong Phase 2 Menopause Data For ABCL635 - Has The Bull Case Changed?AbCellera Biologics recently reported that its investigational antibody ABCL635 achieved statistically significant Phase 2 results, with a single 600 mg subcutaneous dose reducing both the frequency a...
1 heure il y a · Simply Wall St.
AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz DealThe latest analyst update on AbCellera Biologics reflects a higher Fair Value estimate of US$14.63 compared with the prior figure of US$10.43. This shift aligns with more constructive Street research ...
10 heures il y a · Simply Wall St.
AbCellera Biologics (ABCL) Could Be 33% Overvalued Following ABCL635 Phase 2 ResultsWhy ABCL635’s Phase 2 data matters for AbCellera Biologics stock AbCellera Biologics (ABCL) has become a focus for many biotech investors after announcing that ABCL635 met primary endpoints in a Phase...
16 heures il y a · Simply Wall St.
AbCellera Biologics (ABCL) Gets Its First Pipeline Win With Positive Phase 2 DataAbCellera Biologics (NasdaqGS:ABCL) reports positive top line Phase 2 results for ABCL635, its non hormonal antibody treatment for moderate to severe menopausal vasomotor symptoms. The trial shows cli...
21 heures il y a · Simply Wall St.
Is AbCellera Biologics (ABCL) Fully Valued After Its 172% Run?AbCellera Biologics stock has surged year to date, yet the company scores poorly on broad valuation checks and currently screens as expensive on market multiples. After a strong run supported by posit...